Last reviewed · How we verify
NCT02413021
Phase 1 Study of Deferasirox in Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
Phase 1 trial testing Cytarabine in Acute Myeloid Leukemia in 40 participants. Status unknown.
1 August 2016
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2016 |
| Primary completion | 1 August 2016 |
| Estimated completion | 1 October 2016 |
Drugs / interventions tested
- Cytarabine — full drug profile →
- Deferasirox (DEFERASIROX) — full drug profile →
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Acute Lymphoid Leukemia — all drugs for Acute Lymphoid Leukemia →
Sponsor
Isfahan University of Medical Sciences
Who can join
15 and older, any sex, with Acute Myeloid Leukemia or Acute Lymphoid Leukemia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
complete Remission
Time frame: first month
Sponsor's own description
The purpose of this study is to determine whether deferasirox is effective in the treatment of acute lymphatic leukemia (ALL) and acute Myeloid leukemia (AML).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Iron and leukemia: new insights for future treatments.
Wang F, Lv H, Zhao B, Zhou L, et al · · 2019 · cited 104× · PMID 31519186 · DOI 10.1186/s13046-019-1397-3 -
Understanding the Potential and Risk of Bacterial Siderophores in Cancer.
Pita-Grisanti V, Chasser K, Sobol T, Cruz-Monserrate Z. · · 2022 · cited 12× · PMID 35785195 · DOI 10.3389/fonc.2022.867271 -
Linking Iron Metabolism, Ferroptosis, and Cancer: New Targets and Prospects for Effective Anticancer Therapeutic Interventions.
Kourti M, Kontoghiorghes GJ. · · 2026 · PMID 42122232 · DOI 10.3390/cancers18091436
Verify or expand the search:
- PubMed search for NCT02413021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cytarabine
Trials testing the same drug.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07428486 — A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractor · Phase 1 · not yet recruiting
- NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02413021 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 24 February 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02413021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing